Skip to main content

Table 5 Median rank of treatments according to PASI 75 response in each of the five networks

From: Patient characteristics as effect modifiers for psoriasis biologic treatment response: an assessment using network meta-analysis subgroups

TreatmentMedian rank (95% CrI)
Licensed doses N = 69No previous biologic use (< 25%) N = 34PASI score ≤ 25 N = 59Weight ≤ 90 kg N = 27≥ 90% white patients N = 42
Adalimumab11 (8–14)11 (8–12)10 (7–12)9 (5–11)10 (7–12)
Apremilast17 (16–18)15 (14–16)16 (15–16)14 (13–14)16 (15–16)
Brodalumab3 (1–6)4 (1–7)3 (2–5)2 (1–4)4 (2–6)
Certolizumab 200 mg13 (9–15)8 (2–13)12 (9–12)11 (7–12)12 (8–13)
Certolizumab 400 mg10 (7–13)6 (1–11)9 (7–11)8 (5–11)9 (6–11)
DMF18 (17–18)16 (14–16)17 (17–17)17 (17–17)
Etanercept 25 mg16 (15–17)14 (14–15)14 (13–16)
Etanercept 50 mg (twice per week)15 (14–15)13 (12–13)13 (13–13)12 (11–12)13 (12–14)
Etanercept 50 mg (once-weekly)14 (10–16)14 (14–15)15 (14–16)13 (13–14)15 (13–16)
Guselkumab2 (1–6)3 (1–7)2 (2–5)6 (2–12)
Infliximab5 (2–8)3 (1–7)6 (3–7)6 (3–10)5 (3–9)
Ixekizumab1 (1–4)1 (1–4)1 (1–1)1 (1–5)2 (1–3)
Risankizumab4 (1–8)
Secukinumab4 (2–7)5 (2–7)4 (2–6)3 (1–5)1 (1–3)
Tildrakizumab7 (4–12)7 (4–9)5 (3–7)4 (2–7)4 (3–7)
Ustekinumab 45 mg10 (8–13)11 (8–12)9 (8–12)8 (5–11)9 (6–12)
Ustekinumab 45 mg/90 mg11 (8–14)10 (7–12)10 (7–12)8 (5–11)10 (6–12)
Ustekinumab 90 mg8 (5–10)9 (7–12)7 (6–8)6 (1–11)7 (5–9)
Total number of treatments1816171417